June 8, 2020
Chugai Pharmaceutical said on June 5 that it submitted an application seeking the expanded use of FoundationOne CDx Cancer Genomic Profile as a companion diagnostic for AstraZeneca’s PARP inhibitor Lynparza (olaparib) for the treatment of metastatic castration-resistant prostate cancer (mCRPC)...read more